The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer |
| |
Authors: | Yoshida Yoshio Kurokawa Tetsuji Sawamura Yoko Shinagawa Akiko Okazawa Hidehiko Fujibayashi Yasuhisa Kotsuji Fumikazu |
| |
Affiliation: | Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Matsuoka-cho, Yoshida-gun, Fukui-ken 910-1193, Japan. yyoshida@fmsrsa.fukui-med.ac.jp |
| |
Abstract: | BACKGROUND: The positron emission tomography (PET) with F18 17beta-estradiol (FES) has good imaging for assessment of estrogen receptor in breast cancer. CASE: We report on a 30-year-old woman who desired to preserve her fertility with well-differentiated endometrial adenocarcinoma. Before hormone treatment was started, FES-PET showed increased uptake of endometrium, magnetic resonance imaging (MRI) showed thickness and F-18 fluorodeoxyglucose (FDG)-PET showed increased uptake. FES-PET after 3 months showed remaining FES uptake, but there were no abnormal findings on MRI and FDG-PET. Hysteroscopy showed remaining adenocarcinoma. After additional treatment, FES-PET showed a therapeutic response, and hysteroscopy showed no abnormal finding. CONCLUSIONS: To our knowledge, this is the first report that FES-PET has the potential to provide more useful information than did FDG-PET about the hormone therapy. |
| |
Keywords: | FES-PET Endometrial cancer Endocrine treatment |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|